asthma clinical study program. Efficacy data from four pivotal studies were also analyzed. 
INTRODUCTION
Asthma is one of the most common chronic diseases with an estimated 300 million people diagnosed worldwide [1] . International guidelines for asthma treatment recommend the combination of long-acting b 2 -receptor agonist (LABAs) with inhaled corticosteroids (ICSs) as maintenance therapy in patients who remain symptomatic despite receiving low-to-medium doses of ICSs [1, 2] .
Although many treatment options are available, asthma morbidity remains high, with an estimated 346,000 deaths annually worldwide [1, 3] . Despite treatment, the incidence of uncontrolled asthma remains high with a recent European survey of 8000 subjects with asthma showing that 45% of patients with asthma had uncontrolled disease [4] . Poor control often limits activity, and causes breathlessness and sleep difficulties. Patients with poorly controlled disease also experience more absenteeism and work impairment than those with asthma that is at least well controlled [4] .
Asthma-related deaths, increased
exacerbations, and poor disease control have been associated with non-adherence to medication [5] , which is reported to be common in this patient population [6, 7] . A report from the UK suggested that 65% of asthma-related deaths occurring between February 2012 and January 2013 were due to patient-related factors, including non-adherence to medication [8] . Non-adherence to medication is a key factor contributing to poor disease control, which leads to more frequent visits to healthcare professionals, an increase in healthcare costs, and a reduction in health-related quality of life [9] and may be improved with once-daily dosing [10] .
GSK has conducted a large complex program of Phase II and III clinical studies in more than 12,000 adults and adolescents with asthma to evaluate the efficacy and safety of fluticasone furoate/vilanterol (FF/VI), a once-daily ICS/ LABA combination therapy administered as a single fixed dose using the ELLIPTA Ò dry powder inhaler (GSK, Brentford, London). Two doses of FF/VI (200/25 and 100/25 lg) have been approved as maintenance therapy for patients with asthma in the USA [11] , Europe [12] [13] [14] , Japan [15] , and a number of other countries. [24] , NCT01498679 (HZA113719; data on file), NCT01147848 (HZA113091) [25] , NCT01436071 (FFA115283) [26] , NCT014 36110 (FFA115285) [27] , NCT01159912 (FFA112059) [28] , NCT01431950 (FFA114496) [29] , NCT01181895 (B2C112060) [30] , NCT01018186 (HZA106839) [31] , and NCT01 086410 (HZA106851) [32] are Phase III studies.
Across all studies, eligible patients were C65 years 65 (6) 74 (8) 178 (8) 42 (7) 144 (7) 14 (6) Race, n (%) (9) 167 (8) 9 (4) African American 67 (6) 62 (6) 124 (5) 29 (5) 126 (6) 19 (9) Mixed race 75 (7) 14 (1) 125 (5) 41 (7) 151 (8) 
RESULTS
The cut-off date for all data included in this Demographic characteristics for the key treatment groups are provided in Table 1 . The proportion of males to females and the mean age were similar across these groups. The majority of patients in each treatment group were aged 18-64 years and the majority were Caucasian. The mean duration of asthma ranged from 15 to 18 years.
Cumulative exposure varied widely across the key treatment groups, which is likely to reflect the differing duration of these studies (range of 4-76 weeks). The highest exposure was reported for the FF/VI 100/25 group (1537 patient years; key treatment groups displayed in Table 2 ). More than half (59%) of the FF/VI 100/25 patients were in studies of C24 weeks' duration. As patients may not receive a long-term placebo, no patient was exposed to placebo for more than 28 weeks. Most (63%) of the patients who were randomized to receive placebo were in studies of \12 weeks' duration.
Safety Analysis
The most frequently reported common AEs were headache, nasopharyngitis, and upper respiratory tract infection (key treatment groups displayed in Table 3 ). The incidence of some events was numerically higher in the FF/ VI 100/25 group compared with the placebo group.
However, there was no notable difference in exposure-adjusted incidence across treatment groups with the exception of oropharyngeal pain, for which the incidence was numerically greater in the FF/VI 200/25 group than the FF/VI 100/25 group, and back pain, which was reported at a numerically higher incidence in all active treatment groups compared with placebo. Figure 2a presents the incidence of AEs reported by C3% of patients for FF/VI 100/25 compared with placebo (in those studies that included both FF/VI 100/25 and placebo) and shows that the incidence is similar (95% CI for the FF 100 group (stage IV lung cancer, and sepsis and pneumonia); none of these was determined to be asthma-related or considered to be related to the study medication. One patient in the placebo group died of an unknown cause. Table 3 Adverse events reported by C3% of patients, by treatment group 
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Headache 74 (7) 85 (9) 322 (14) 44 (7) 260 (13) 17 (8) Nasopharyngitis 59 (6) 76 (8) 277 (12) 53 (9) 207 (10) 9 (4) Upper respiratory tract infection 30 (3) 52 (5) 155 (7) 15 (2) 123 (6) 4 (2) Bronchitis 16 (1) 24 (3) 80 (3) 15 (2) 104 (5) 0 Oropharyngeal pain 13 (1) 27 (3) 72 (3) 19 (3) 75 (4) 7 (3) Cough 13 (1) 18 (2) 86 (4) 13 (2) 74 (4) 0 Sinusitis 8 (\1)
16 (2) 70 (3) 15 (2) 55 (3) 0 Back pain 4 (\1)
22 (2) 66 (3) 11 (2) 59 (3) 2 (\1)
19 (2) 64 (3) 17 (3) 49 (2) 1 (\1) Pharyngitis 26 (2) 11 (1) 52 (2) 8 (1) 60 (3) 2 (\1) The incidences of AESIs across the key treatment groups are presented in Pneumonia was reported by \1% of patients in any of the key treatment groups.
Investigators determined the diagnosis of pneumonia and were requested, but not mandated, to provide X-ray confirmation. Of the 40 patients in the key treatment groups who reported a pneumonia event, only 27 patients received a chest X-ray, and pneumonia was confirmed by X-ray in 25 of them ( Table 7) . The incidence of X-ray confirmed pneumonia was \1% in all the active treatment groups, compared with \0.1% in the placebo group ( Table 7 ).
The safety of FF/VI in patients with asthma was evaluated in subpopulations based on age, gender, race, and region. The incidences of AEs in these subgroups were similar to the incidence in the ITT population across the key treatment groups.
The change from baseline in heart rate by treatment group is shown in Fig. 3 . The mean baseline heart rates across the six key treatment groups ranged from 69.5 to 72.4 beats per minute. The maximum mean change from baseline at 24-h pre-dose was \1 beat per minute for the FF/VI and placebo groups.
Data from ten clinical studies (n = 2547) were used to assess urine free cortisol excretion (key treatment groups displayed in Table 8 ). At baseline, the geometric means for 24-h UC excretion ranged from 57.46 to 64.30 nmol/ 24 h across the five treatment groups. At the end of treatment, the 24-h UC excretion geometric means were numerically similar to baseline.
There were no statistically significant differences in the asthma composite endpoint (defined as asthma-related hospitalizations, intubations, or death) analysis of all FF/VI doses versus all ICS doses (i.e., the 95% CIs for the difference all included zero; Fig. 4 
Efficacy Analysis
Data for trough and weighted mean FEV 1 for the four pivotal studies are shown in Fig. 5 . There was a statistically significant difference in trough FEV 1 (p\0.014; Fig. 5a ) and 0-24 h weighted mean FEV 1 (p\0.048; Fig. 5b) between the FF/VI and FF treatment groups in all studies, with the exception of NCT01165138.
It is notable that in the NCT01165138 study 
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Local steroid effects 17 (2) 70 (7) 155 (7) 48 (8) 131 (7) 7 (3) Oropharyngeal pain
13 (1) 27 (3) 72 (3) 19 (3) 75 (4) 7 (3) Dysphonia 4 (\1)
15 (2) 52 (2) 11 (2) 26 (1) 0 Oral candidiasis 0 19 (2) 27 (1) 8 (1) 19 ( 17 (2) 27 (3) 92 (4) 19 (3) 123 (6) 2 (\1) Bronchitis 16 (1) 24 (3) 80 (3) 15 (2) 104 (5) 0 Cardiovascular effects 12 (1) 46 (5) 102 (4) 14 (2) 65 (3) 4 ( 35 (1) 7 (1) 21 (1) 1 (\1) Hypersensitivity b 17 (2) 22 (2) 54 (2) 6 (\1) 43 (2) 2 (\1) (Fig. 7) . The widths of the CIs are a reflection of the sample size.
Benefit:risk Ratio
The benefit:risk ratio of FF/VI 200/25 versus FF/ VI 100/25 and FF/VI 100/25 versus FF 100 is shown in Fig. 8 . The combination of FF with VI [31] , and this was the only study to include FF/VI 200/25, FF/VI 100/25, and twice-daily FP 500. The low incidences of X-ray confirmed pneumonia observed across all key treatment groups are consistent with the background rate in the asthma population, and for FF/VI 200/25, the exposure-adjusted rates are similar to the exposure-adjusted rates of pneumonia that were reported for placebo, FP, and budesonide in a meta-analysis of data from budesonide studies [33] .
The use of LABA monotherapy in asthma has been associated with potential increased risk of serious asthma-related outcomes [34] , although the same concern has not been shown with ICS/ LABA combination therapies [35] . This integrated analysis was performed on a large patient database ([7000 patients), with 46% of these patients receiving the approved dose of FF/VI (i.e., 200/25 or 100/25 lg), and consisted of a rigorous assessment of pharmacologically predictable effects, such as cortisol suppression and effects on heart rate, and independent adjudication for the asthma composite endpoint. One limitation of this analysis is that there were differences between the studies in the populations, treatments, and treatment durations, which precluded the integration of efficacy endpoints other than FEV 1 , at week 12, such as rescue-free days and withdrawals. The difference in treatment durations also limits the interpretation of long-term effects, as the longest duration of treatment with placebo was 24 weeks compared with 76 weeks for FF/VI and FF. In the subgroup analysis by race and age, some treatment groups were small in size. 
